Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2010

View Archived Issues

TCF4 gene variation implicated in Fuchs' corneal dystrophy

First selective Aurora kinase A inhibitors identified

Fixed-dose fenofibrate/pravastatin plus ezetimibe reduces hyperlipidemia in type 2 diabetes

High loading dose of clopidogrel may overcome effects of CYP2C19 genetic variant in persons with CAD

Multiple dosing of AMG-853 well tolerated in healthy volunteers

Kowa discloses new angiotensin antagonists/PPARgamma ligands

New inhibitors of IgE Fc receptor described by Fujitsu

Favorable safety and pharmacokinetics seen in phase I trials of anti-CMV agent AIC-246

New vancomycin carbamate derivative shows potent antibacterial activity in drug-resistant strains

FDA grants orphan drug status for DasKloster-0210

Micromet begins phase II trial of its BiTE antibody blinatumomab in ALL

FDA provides guidance to Apricus on phase III study RayVa trial

Global Health Ventures begins developing sublingual telcagepant for migraine

Topica announces sublicensing agreement for luliconazole for tinea infections

PTC receives FDA grant for phase III cystic fibrosis trial

Celldex begins phase IIb trial of CDX-011 in breast cancer

Relypsa completes financing round to support RLY-5016 development

Phase III TAMARIS trial in critical limb ischemia fails to meet primary endpoint

Cytokinetics and Amgen plan phase IIb trial of omecamtiv mecarbil in HF

Phase II trial of AERAS-402 TB vaccine candidate initiated in Kenya

FDA grants Novartis approval for Gilenya for the treatment of relapsing MS

Santhera to file MAA for use of Catena in Leber's hereditary optic neuropathy

Vermillion receives CE mark for OVA1 test for ovarian cancer detection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...